logo

For the Inventor, By the Inventor

Acton, MA, United States of America

Hua Zhou

This inventor holds 28 USPTO granted patents and 3 published patent applications and 23 EPO patents. Top assignees: Merck Sharp + Dohme Corp., Merck Canada Inc., Iomet Pharma Ltd.. Active years: 2013-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hua Zhou. Retrieved from https://idiyas.com/inventor/hua-zhou-vevr5ii2

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 28 

% Patents Active = 96.4

 

Average Co-Inventor Count = 12.8

ph-index = 4

Forward Citations = 56(Granted Patents)


Company Filing History:

goldMedal28 out of 2,405 
 
Merck Sharp + Dohme Corp.
 patents
silverMedal3 out of 40 
 
Merck Canada Inc.
 patents
bronzeMedal2 out of 10 
 
Iomet Pharma Ltd.
 patents
where one patent can have more than one assignee

Years Active: 2013-2025

Loading Chart...
Loading Chart...
28 patents (USPTO):Explore Patents
1. 12319671 - 1-pyrazolyl, 5-, 6-disubstituted indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof (2025-06-03),
2. 12157727 - Substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors (2024-12-03),
3. 12065438 - Substituted tricyclic compounds as indoleamine 2,3-dioxygenase inhibitors (2024-08-20),
4. 12030872 - N-heteroaryl indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof (2024-07-09),
5. 11319283 - Substituted cyclobutylbenzene compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors (2022-05-03),
6. 11230547 - Purine inhibitors of human phosphatidylinositol 3-kinase delta (2022-01-25),
7. 11208407 - Substituted phenyl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors (2021-12-28),
8. 11179389 - Purine inhibitors of human phosphatidylinositol 3-kinase delta (2021-11-23),
9. 11111232 - Substituted cyclobutylpyridine and cyclobutylpyrimidine compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors (2021-09-07),
10. 11103493 - Substituted pyridinyl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors (2021-08-31),
11. 11096930 - Substituted imidazopyridine compounds as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan-2,3-dioxygenase (2021-08-24),
12. 10995085 - Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors (2021-05-04),
13. 10647705 - Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors (2020-05-12),
14. 10544147 - Purine inhibitors of human phosphatidylinositol 3-kinase delta (2020-01-28),
15. 10538497 - Compounds as indoleamine 2,3-dioxygenase inhibitors (2020-01-21),

Title: Hua Zhou: Pharmaceutical Patent Inventor in Acton, Massachusetts.

Introduction

Hua Zhou is an inventor based in Acton, Massachusetts, whose patent work includes pharmaceutical compounds and potential treatments for diseases. His portfolio includes 28 patents, and his listed company affiliations include Merck Sharp & Dohme Corp. and Merck Canada Inc.

Latest Patents

One of Zhou’s latest patents concerns 1-pyrazolyl, 5-, 6-disubstituted indazole derivatives as LRRK2 inhibitors, along with pharmaceutical compositions and uses for these compounds. The disclosed derivatives are described as potent LRRK2 kinase inhibitors and may have potential applications in preventing or treating Parkinson’s disease and other conditions involving the kinase.

Another patent concerns substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors. It describes compounds and pharmaceutical compositions that may be used in the potential prevention or treatment of IDO-associated diseases and disorders.

Career Highlights

Zhou’s listed affiliations with Merck Sharp & Dohme Corp. and Merck Canada Inc. connect his patent activity with pharmaceutical research and development. His disclosed inventions focus on medicinal chemistry and potential therapeutic applications.

Collaborations

Zhou’s listed coworkers include Meredeth Ann McGowan and Yongxin Han. Their names appear alongside his work in the patent information provided.

Conclusion

Hua Zhou’s patent portfolio reflects work on investigational compounds and pharmaceutical approaches, including potential treatments involving LRRK2 and IDO.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…